ASX MEDIA RELEASE 7 JUNE, 2006 NOVOGEN RENEGOTIATES PHENOXODIOL LICENCE PAYMENT Novogen Limited (ASX: Novogen Nasdaq: NVGN) has renegotiated with Marshall Edwards, Inc. (Nasdaq: MSHL) the timing of an $US8 million milest

RENEGOTIATES PHENOXODIOL LICENCE PAYMENT

Limited (ASX: Novogen Nasdaq: NVGN) has renegotiated with Marshall Edwards, Inc.

MSHL) the timing of an $US8 million milestone licence payment for phenoxodiol payable to

Novogen Limited in December 2006, under the terms of the Licence Agreement for the anti-cancer drug

The terms of the Amendment Deed signed today, postpones the licence fee payment until

phenoxodiol receives first approval for marketing the product in the USA or any other country. The marketing

approval may be by the receipt of a New Drug Application under Accelerated Approval or otherwise.

MSHL s President and CEO, Mr. Naughton, said the postponing of the licence fee payment would

enable MSHL to focus its cash resources on completing the phase Ill clinical trial for which it had

recently received approval of its Special Protocol Assessment from the US Food and Drug Administration (FDA).

The milestone licence payment is now due when phenoxodiol is approved for market by the FDA.

Edwards, Inc. (Nasdaq : MSHL) is a US clinical oncology company and is majority owned

Novogen Limited (ASX: NRT Nasdaq: NVGN), based in Sydney, Australia, is developing a range

of therapeutics across the fields of oncology, cardiovascular, and inflammatory diseases.

More information on phenoxodiol and on the Novogen group of companies can be found at

www.marshalledwardsinc.com and www.novogen.com.